Article Details
Retrieved on: 2024-11-23 05:26:28
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Pfizer's tafamidis capsules, sold as Vyndaqel and Vyndamax, were approved in 2019 and brought in sales of $3.32 billion in 2023. BridgeBio's ...
Article found on: www.newsbreak.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here